Navigation Links
Amgen's Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
Date:10/22/2008

ates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.

Amgen Inc.

Condensed Consolidated Statements of Income and

Reconciliation of GAAP Earnings to "Adjusted" Earnings

(In millions, except per share data)

(Unaudited)

Three Months Ended Three Months Ended

September 30, 2008 September 30, 2007

----------------------------- ------------------------------

GAAP Adjustments "Adjusted" GAAP Adjustments "Adjusted"

----------------------------- ------------------------------

Revenues:

Product

sales $3,784 $- $3,784 $3,524 $- $3,524

Other

revenues 91 - 91 87 - 87

------- ------- ------- ------- ------- -------

Total

revenues 3,875 - 3,875 3,611 - 3,611

------- ------- ------- ------- ------- -------

Operating

expenses:

Cost of sales

(excludes

amortization

of acquired

intangible

assets

presented

below) 677 (3) (a) 590 792 (4) (a) 585

(84) (b) (113) (e)

(90) (h)

Research and

development 729 (12) (a) 700 776 (20) (a) 699

(17) (c) (18) (e)


'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. CNS Response Announces Fiscal Third Quarter 2007 Results
2. Avitar Reports Third Quarter Financial Results for Fiscal 2007
3. Martek to Announce Third Quarter 2007 Results on September 5, 2007
4. Third Security, LLC Hires Two New Managing Directors
5. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
6. ThirdBiotech Networking Group Launches
7. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
8. PPD Announces Third Quarter 2007 Earnings Release, Webcast and Conference Call
9. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
10. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
11. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) ... Chief Financial Officer has resigned.  The Company has hired ... who retired in December 2014, as full time interim ... successor.     Andy Ashworth began his ... a smooth transition.  Andy was the Company,s CFO from ...
(Date:7/29/2015)... ... 29, 2015 , ... Brady (NYSE:BRC), a global leader in ... To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard and ... example of an accurate label, and pictogram uses and meanings. , “With changes ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Brady Announces a New GHS Label Guide 2
... ... ... Inc., a stem cell,engineering company, today announced data demonstrating for the first time,that ... insulin in mice. The findings are reported in an,article appearing on-line today, in ...
... net revenues grew 29.8%, as compared to Q4 2006, to RMB45.7 ... - Q4 2007 net income grew 152.2%, as compared to Q4 2006, to RMB17.9 ... (US$2.5 million), - 2007 fiscal year net revenues increased 41.0% year-over-year to RMB180.2 ... 2007 fiscal year net income grew 167.4% year-over-year to RMB81.5 million ...
... 20 Addrenex,Pharmaceuticals has reached its first milestone ... drug application (NDA) for its first drug,CloniBID, to ... Drug,Administration, Addrenex and its licensing partner Sciele Pharma, ... of 2009., Addrenex has moved swiftly to ...
Cached Biology Technology:Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice 2Novocell Reports Successful Use of Stem Cells to Generate Insulin in Mice 33SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results 16Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension 2
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... meeting next week may decide the fate of tuna in ... marine resources. The Inter-American Tropical Tuna Commission (IATTC) ... 27 in Panama City, Panama, to reverse a trend of ... tuna stocks. Failure of the IATTC to compromise effectively in ...
... N.Y., June 17 bioMETRX, Inc. (OTC,Bulletin Board: ... today announced that the Handgun Club of America ... are showing great interest in,bioMETRX,s smartTOUCH(TM) bioVAULT 2.0 ... with the touch of a finger, and recognition,taking ...
... latest state of the environment report, released today, ... issues facing the NAFTA partners. The report ... and ecosystems, and pollution. Specific topics include climate ... porpoiseand the quality and quantity of water shared ...
Cached Biology News:Tuna populations at risk 2bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 2bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America 3New report looks at the state of the North American environment 2
Incomplete Adjuvant...
... Lacks the mycobacteria found ... side-effects. For this reason, Incomplete, ... Freund's Adjuvants may be used to produce water-in-oil ... emulsions stimulate high and long-lasting antibody responses which ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: